R&D/Clinical Trials

Latest News

Eli Lilly’s Zepbound Demonstrates Superior Weight Loss to Wegovy in Adults With Obesity or Overweight
Eli Lilly’s Zepbound Demonstrates Superior Weight Loss to Wegovy in Adults With Obesity or Overweight

December 4th 2024

Results from the SURMOUNT-5 Phase IIIb trial found that Zepbound achieved an average weight loss of 20.2%, surpassing Wegovy’s 13.7%.

Biohaven’s Taldefgrobep Alfa Fails to Achieve Statistical Significance in Treating Spinal Muscular Atrophy
Biohaven’s Taldefgrobep Alfa Fails to Achieve Statistical Significance in Treating Spinal Muscular Atrophy

November 26th 2024

Russell Hayward
Developing Therapies for Treatment Resistant Cancers: Q&A with Russell Hayward

November 18th 2024

A New Schizophrenia Treatment: What the Approval of Cobenfy Could Mean for Handling Mental Health Disorders
A New Schizophrenia Treatment: What the Approval of Cobenfy Could Mean for Handling Mental Health Disorders

November 18th 2024

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

November 14th 2024

More News